AstraZeneca's Tezspire recommended for US approval, Elixirr reports record interim results.


LONDON PRE-OPEN The FTSE 100 was expected to open 11.6 points softer ahead of the bell on Monday after wrapping up the previous session 0.12% lower at 9,216.67.

Tower Bridge in London

Source: Sharecast

STOCKS TO WATCH

AstraZeneca and Amgen said on Monday that their Tezspire drug has been recommended for approval in the European Union for the treatment of adult patients with chronic rhinosinusitis with nasal polyps. The European Medicines Agency based its positive opinion on results from a phase three trial, which demonstrated a "statistically significant and clinically meaningful reduction" in nasal polyp severity, and removed the need for surgery in 98% of cases.

Business consultancy Elixirr International has reported record interim results and reiterated its full-year forecasts, with the outlook bolstered by last week's acquisition of US strategy consultancy TRC. Elixirr reported a 35% increase in first-half revenues to £71.4m, with organic revenues up 17%, while adjusted underlying earnings surged 42% to £21.5m.

NEWSPAPER ROUND-UP

Gatwick Airport's £2.2bn second runway plan has been given the go-ahead by the transport secretary, Heidi Alexander. With the privately financed project, the West Sussex hub is aiming to increase its capacity by 100,000 flights a year. Gatwick will move its emergency runway 12 metres north, enabling it to be used for departures of narrow-bodied planes such as Airbus A320s and Boeing 737s. – Guardian

Vodafone franchisees warned the telecoms group of the "massive impact" commission cuts were having on their mental health four years before a group of 62 launched a £120m high court claim against the company, it has emerged. Franchisees of the high street chain said they were feeling stressed and had suffered from "anxiety" as a result of the decision to cut fees, in research that also indicated they had little trust in Vodafone's word. – Guardian

Britain is battling a glut of empty lab space after a string of pharmaceutical companies pulled investment from the country. The vacancy rate across life sciences buildings has more than doubled to a record high of 9.9% over the past year, according to new figures from property analytics firm CoStar. – Telegraph

An Irish entrepreneur has unveiled plans to build a vast new gas storage site in the eastern Irish Sea to help protect Britain from the threat of blackouts. Tony O'Reilly Jr, son of the former billionaire boss of Heinz, said the proposed facility would provide an "insurance policy" as the national electricity system becomes more dependent on intermittent renewables. – Telegraph

The fallout from the car loans mis-selling scandal has intensified after the British motor finance business of BMW revealed it had set aside more than £200m to cover its potential compensation bill. The disclosure by the German carmaker comes as banks and other providers of motor finance brace for the Financial Conduct Authority, which is the City regulator, to set out the details of its plan for an industry-wide redress scheme that could cost firms as much as £18bn. Millions of drivers are expected to receive payouts from lenders worth hundreds of pounds each. – The Times

American buyers of British exports have paid $1.36bn in tariffs in the four months since President Trump's "liberation day" shock, six times more than in the corresponding period of 2024 and more than for several rival European exporting nations, including France and Spain. Estimates from the US International Trade Commission reveal the scale of the hit to British manufacturers and suggest Britain is being heavily penalised in spite of concessions won by the British government. – The Times

US CLOSE

Wall Street stocks were higher at the closing bell on Friday, with all three major indices extending their record-setting rally.

At the close, the Dow Jones Industrial Average was up 0.37% at 46,315.27, while the S&P 500 advanced 0.49% to 6,664.36, and the Nasdaq Composite saw out the session 0.72% firmer at 22,632.48.

Reporting by Iain Gilbert at Sharecast.com

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.